GRI Bio Inc (GRI) reported a Q3 2024 non-revenue quarter with a net loss of $2.123 million on operating expenses of $2.13 million and an EBITDA of -$2.129 million. The absence of revenue in a Phase II/Phase I clinical-stage biotech underscores the company’s early-stage operating profile and its dependence on external financing to sustain R&D activities. Cash and cash equivalents stood at $4.746 million at quarter-end, with net cash burn from operating activities of $2.269 million for the period; financing activities provided a net $0.661 million, and the company ended the period with a net decrease in cash of $1.607 million. The balance sheet shows modest current assets relative to a modest liability base, and a substantial accumulated deficit reflected in negative retained earnings, highlighting the persistent capital-intensive nature of biotech R&D and the need for ongoing fundraising to advance the pipeline.
GRI’s pipeline spans GRI0621 (Phase II for idiopathic pulmonary fibrosis), GRI0803 (Phase I for systemic lupus erythematosus), and preclinical programs (GRI0124 for primary sclerosing cholangitis, GRI0729). Additionally, ADAIR/ADMIR targets ADHD, signaling a diversified but early-stage portfolio. In the near term, investors should monitor clinical milestones, potential licensing or collaboration deals, and the company’s ability to secure additional equity or debt financing to fund ongoing development. Absent an earnings call transcript in the provided data, management commentary is not embedded here, limiting the inclusion of direct quotes and nuanced qualitative takeaways from leadership.